
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Centre National de la Recherche Scientifique, UMR 5641, Lyon, France [S. M. G., S. M.]; Centre International de Recherche sur le Cancer, Lyon, France [S. M. G., M. C., C. S., D. G., G. M. L., O. M. S.]; Institut National de la, France Santé et de la Recherche Médicale (INSERM) U509, Service de Génétique Oncologique, Institut Curie, Paris, France [S. Ga., D. S-L.]; Institut Gustave Roussy, Villejuif, France [B. B-d-P., A. C.]; Centre Jean Perrin, Clermont-Ferrand, France [Y-J. B.]; Centre Oscar Lambret, Lille, France [J-P. P., J. F.]; Centre Léon Bérard, Lyon, France [C. L.]; Hospices Civils de Lyon, Lyon, France [S. Gi., O. M. S.]; Centre Paul Strauss, Strasbourg, France [D. M., J-P. F.]; Centre François Baclesse, Caen, France [A. H., P. B.]; Centre René Gauducheau, Nantes, France [C. M.]; Centre René Huguenin, St. Cloud, France [C. N., R. L.]; Institut Bergonié, Bordeaux, France [M. L.]; Centre dEtudes Polymorphisme des Humains, Paris, France [S. O.]; Institut Claudius Regaud, Toulouse, France [C. T., R. G.]; National Center for Scientific Research Demokritos, Athens, Greece [D. Y.]; Centre Hospitalo Universitaire Laval, Quebec, Canada [F. D., A-M. M., J. S.]; Consortium Interdisciplinary Health Research International Team on Breast Cancer Susceptibility (INHERIT BRCAs) [F. D., A-M. M., J. S.]; and Creighton University, Omaha, Nebraska [H. T. L.]
Strong inter- and intrafamilial variation of penetrance of breast and ovarian cancer is observed in BRCA1 mutation carriers. The wild-type copy of the BRCA1 gene is a plausible candidate as a cancer risk modifier given that the residual function corresponding to the intact BRCA1 allele may influence the process of tumor formation in BRCA1 carriers. Indeed, growing evidence is now becoming available on impaired reparation of double-strand DNA breaks in cells heterozygous for BRCA1 mutations, implying an enhanced mutability of BRCA1+/- cells. To determine whether certain variant forms of the wild-type BRCA1 allele are implicated in variation of the BRCA1-related cancer risk, their effect was studied in a panel of 591 women with BRCA1 germ-line mutations. We found that BRCA1 carriers with the wild-type BRCA1 copy bearing a common Gly1038 variant were at increased risk of ovarian cancer (hazards ratio, 1.50; 95% confidence interval, 1.032.19). The results of our study imply that a quite significant proportion of the interindividual variability in ovarian cancer penetrance in BRCA1 carriers may be explained by a common BRCA1 Gly1038 wild-type allele, given its high frequency (0.27).
This article has been cited by other articles:
![]() |
D. J. Hughes, S. M. Ginolhac, I. Coupier, M. Corbex, B. Bressac-de-Paillerets, A. Chompret, Y.-J. Bignon, N. Uhrhammer, C. Lasset, S. Giraud, et al. Common BRCA2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA1 Mutation Carriers Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 265 - 267. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |